CO-AX accelerator at Sahlgrenska Science Park invites trailblazing healthtech entrepreneurs for spring 2024 intake
Building on its legacy of fostering impactful healthtech innovations, the CO-AX accelerator at Sahlgrenska Science Park opens its doors for the spring 2024 batch of entrepreneurial talent. This call is directed towards innovators and startups who are leveraging technology to address global health challenges.
Publish date:2024-01-23–Text:
Jamie Smith
As a leading accelerator in the healthtech domain, CO-AX offers a unique platform for visionary entrepreneurs to transform their ideas into impactful healthcare solutions. The CO-AX programme is dedicated to nurturing healthtech, medtech, biotech and deeptech startups that are at the forefront of addressing critical health issues, from improving patient care to revolutionizing medical diagnostics.
So far, CO-AX has incubated 140 companies who have raised more than Euros 100 million in capital. 32% of CO-AX portfolio companies operate internationally.
Key benefits for participants
Participants in the CO-AX program will receive comprehensive support, including:
Tailored coaching from business advisors, industry experts and mentors
Markets access, including test and verification opportunities
Roadmap to international growth and access to capital
Guidance in regulatory and compliance
Exposure to healthcare professionals
Events, seminars, co-working offices and shared labs.
Annica Grimberg Lignell, Director Business & Innovation and Head of CO-AX at Sahlgrenska Science Park: “CO-AX is a perfect place for deeptech, femtech and AI entrepreneurs who want to make a meaningful impact for caregivers. Our healthtech expertise and vast networks help them unlock the full potential of their innovations and to scale faster. Ideal candidates are innovative tech startups that demonstrate a clear vision for addressing unmet needs in global healthcare.”
Pontus Axblom, Co-founder and CEO at Beat Vascular Health: “We joined CO-AX last year and it has exceeded all our expectations. Everything is geared to help us to grow our business and develop our technology for early detection of cardiovascular disease. The best part is that we get access to a wide range of expertise, but we don’t have to give up a stake in our company to get it. Also, the CO-AX people and parties are legendary!”
